Publication: Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer
Issued Date
2016-08-24
Resource Type
ISSN
14777819
Other identifier(s)
2-s2.0-84983315196
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Surgical Oncology. Vol.14, No.1 (2016)
Suggested Citation
Pattaraporn Wangchinda, Suthinee Ithimakin Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World Journal of Surgical Oncology. Vol.14, No.1 (2016). doi:10.1186/s12957-016-0988-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/41218
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer
Author(s)
Other Contributor(s)
Abstract
© 2016 The Author(s). Background: Occasionally, breast cancer relapses more than 5 years after initial treatment, sometimes with highly aggressive disease in such late-recurring patients. This study investigated predictors of recurrence after more than 5 years in operable breast cancer. Methods: We retrospectively analyzed data from patients with recurrent breast cancer treated at Siriraj Hospital. Patients were divided into those whose relapse times were longer or shorter than 5 years. Factors that predicted late recurrence were analyzed in both the overall population and the luminal subgroup. Patterns of relapse, changes in biomarkers, and time to disease progression after first relapse were also recorded. Results: We included 300 women whose breast cancers recurred between 2005 and 2013, of whom 180 had recurrence within 5 years of diagnosis and 120 later than 5 years (median time to recurrence: 45.43 months; range: 4.4-250.3 months). Tumors larger than 2 cm, lymph node metastasis, and high nuclear grade were related with early recurrence. Estrogen receptor-positive, progesterone receptor-positive, and HER2-disease predicted late recurrence. Almost all late-relapsing patients with luminal tumors had high estrogen receptor (ER+) titers (≥50 %) and HER2-disease. Liver and brain were the most common early recurrence sites. Biomarkers did not significantly change by time of recurrence. Conclusions: ER+/PR+and HER2-patients have higher risk of recurrence later than 5 years, especially in patients with high ER titer and low nuclear grade. Larger and node-positive tumors had higher risk of early recurrence.